Skip to content

Effect of Oncothermia on Improvement of Quality of Life in Unresectable Pancreatic Cancer Patients

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02150135
Enrollment
10
Registered
2014-05-29
Start date
2014-06-30
Completion date
2015-11-30
Last updated
2016-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Pancreas

Keywords

Pancreatic cancer, Quality of life, Pain

Brief summary

Patients with pancreatic cancer often suffer from pain. Because of such a pain, their quality of life have seriously deteriorated. There have been a few studies that showed an effect for pain control by hyperthermia (heating the patient's body). However, there are several limitations in conventional hyperthermia. In this study, the investigators tried to show the effect of Oncothermia which is more selective to malignant tissue than conventional hyperthermia for pain control, increasing quality of life, and anti-tumor treatment.

Interventions

Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.

Sponsors

Hospicare Co., Ltd.
CollaboratorINDUSTRY
Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Inoperable or recurred pancreatic ductal adenocarcinoma * After the each cycle of chemotherapy, the disease status was stable disease

Exclusion criteria

* Person who has an experience of hyperthermia treatment * Person who has a difficulty of sensing heat * Person who has a skin graft or breast reconstruction surgery * Person who has a cardiac pacemaker or an implanted metal * Pregnant or breast feeding women * Person with uncontrolled infection, diabetes, hypertension, ischemic heart disease, myocardial infarct within 6 months * Person who was treated with unproved drugs within 6 months * Person who have a serious disease which can affect the person's safety * Person who do not consent to the study

Design outcomes

Primary

MeasureTime frame
ECOG score change3 months after oncothermia treatment

Secondary

MeasureTime frame
Progression free survival rate3 months later after oncothermia treatment

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026